New antiplatelet therapies for acute coronary syndromes

Jonathan D. Rich, Stephen D. Wiviott*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations


Platelets play a central role in the pathophysiology of acute coronary syndromes (ACS). Dual antiplatelet therapy has resulted in significant advances in the treatment of ACS; however, ACS remains an important cause of morbidity and mortality. Important limitations exist among the current antiplatelet agents and therefore a pressing need for the development of improved antiplatelet agents exists. Three antiplatelet agents currently under investigation (prasugrel, AZD6140, and cangrelor) in clinical trials for the treatment of ACS appear promising.

Original languageEnglish (US)
Pages (from-to)303-311
Number of pages9
JournalCurrent Cardiology Reports
Issue number4
StatePublished - Jul 2007

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'New antiplatelet therapies for acute coronary syndromes'. Together they form a unique fingerprint.

Cite this